The number of COVID-19 cases, especially with pregnancy, remains a problem in the world and in Indonesia. The main clinical symptoms include fever (temperature >38oC), cough, and shortness of breath. ...In addition, it can be accompanied by fatigue, myalgia, gastrointestinal symptoms such as diarrhea, and even recently found manifestations of skin disorders. Skin manifestations in COVID-19 pregnant patients are still a rare condition. Skin manifestations can be an early sign of such infection, which therefore requires clinicians’ notice to allow them to conduct early COVID-19 screening in pregnant women for better outcomes of the mother and the baby. We present a 26-year-old primigravida at 39 weeks of gestational age with premature rupture of membranes and COVID-19 infection. Her complaints included itchy maculopapular rash and urticaria, then the pregnancy was terminated by a caesarean section, and the baby was born with good conditions. The skin lesions were given a mixture of corticosteroid cream and fusidic acid. The mother and the baby were discharged in a good condition.
COVID-19 is associated with a wide range of skin manifestations.
To describe the clinical characteristics of COVID-19–associated skin manifestations and explore the relationships among the 6 main ...cutaneous phenotypes and systemic findings.
Twenty-one Italian Dermatology Units were asked to collect the demographic, clinical, and histopathologic data of 200 patients with COVID-19–associated skin manifestations. The severity of COVID-19 was classified as asymptomatic, mild, moderate, or severe.
A chilblain-like acral pattern was significantly associated with a younger age (P < .0001) and, after adjusting for age, significantly associated with less severe COVID-19 (P = .0009). However, the median duration of chilblain-like lesions was significantly longer than that of the other cutaneous manifestations taken together (P < .0001). Patients with moderate/severe COVID-19 were more represented than those with asymptomatic/mild COVID-19 among the patients with cutaneous manifestations other than chilblain-like lesions, but only the confluent erythematous/maculo-papular/morbilliform phenotype was significantly associated with more severe COVID-19 (P = .015), and this significance disappeared after adjustment for age.
Laboratory confirmation of COVID-19 was not possible in all cases.
After adjustment for age, there was no clear-cut spectrum of COVID-19 severity in patients with COVID-19–related skin manifestations, although chilblain-like acral lesions were more frequent in younger patients with asymptomatic/pauci-symptomatic COVID-19.
The fifth edition of this best-selling Red Book® image companion aids in the diagnosis and treatment of more than 165 pediatric infectious diseases. Streamline disease recognition and clinical ...decision-making with more than 1,350 finely detailed color images, combined with step-by-step guidance.
Because of the increasing emergence of skin manifestations of COVID-19 worldwide, we investigated the published reports of these lesions.
We conducted a literature search for original and review ...articles published from November 11, 2019 to September 30, 2020.
We identified 5 skin lesions common in patients with COVID-19: pseudo-chilblains, rashes containing macules and papules, and urticarial, vesicular, and vaso-occlusive lesions. These lesions manifested at various times in relation to the COVID-19 symptoms, which may indicate whether the lesions are virus-induced or are delayed immunological responses to the infection. Skin lesions were more prevalent among Europeans and United States residents than among Asians, as was pseudo-chilblain, and the morphology of the skin lesions varied among continents. Pseudo-chilblains were the most common COVID-19 skin manifestation in Europe and the United States, but there was only 1 reported case from Asian populations. Additionally, patients with vaso-occlusive lesions were more likely than those with pseudo-chilblains to be admitted to the intensive care unit and to die.
Different cutaneous manifestations in patients with COVID-19 could reflect a wide spectrum of viral interactions with the skin, though reporting bias may play a role as well.
Abstract Background: COVID-19 is a global pandemic caused by SARS_COV2. The symptoms of covid-19 include: fever, dyspnea, fatigue, a recent loss of smell and taste, sore throat, cough, and cutaneous ...lesions. In addition, some skin manifestations were reported to be associated with COVID-19. Methods: The study design is a descriptive cross-sectional hospital-based study. The study aimed to evaluate the level of knowledge and practice about skin manifestations of COVID-19 among doctors working at Khartoum dermatology and venereology teaching hospital. A self-administrated questionnaire was used for data collection after an informed consent was taken. Results: Among 140 doctors working in the dermatology and venereology teaching hospital, 75.7% of the doctors had knowledge that COVID-19 can present with skin manifestations. The study results showed that about half of the participants have poor knowledge about COVID-19 skin manifestations while 25% have no knowledge, and that 35 (25%) doctors have good knowledge. From a total of 140 doctors; 46.4% reported that when patients present with COVID-19 skin lesions, they will isolate them in separate rooms and call the epidemiology center, whereas, 61 doctors (43.6%) did not know if they have a protocol for COVID-19 suspected cases. This study reported a significant association between job category and level of knowledge toward COVID-19 skin manifestations measured by Chi-square test, the P-value was 0.003 (significant at 0.05), and the same significant association was found between the year of rotation and knowledge. Conclusion: Half of the doctors covered by this study had poor knowledge about COVID-19 skin manifestations, and therefore, educating doctors in dermatology hospitals about skin manifestations of COVID-19 is recommended, besides clear and precise guidelines and protocols for diagnosis and management.